Москва. 25 апреля.

Москва. 15 февраля.

Москва. 12 февраля.

Biogen expects “ minimal ” sales this year from its Alzheimer’s treatment initially hailed as a

A new Alzheimer’s drug from Biogen brought in only$ 300, 000 in sales during its first full quarter

Stocks that traded heavily or had substantial price changes Thursday: WD-40 Co., up$ 1.26 to$ 261.80. The maintenance and cleaning product company reported strong fiscal third-quarter financial results. Helen of Troy Ltd., down$ 14.01 to$ 218.51. Investors were disappointed by the personal and household products company's financial forecast. Kansas City Southern, down$ 22.46 to$ 262.79. The Biden administration is reportedly pushing regulators to focus on anticompetitive practices in the railroa

that would generate billions for Biogen. But doctors have been hesitant to prescribe it, given weak

Biogen is slashing the price of its Alzheimer’s treatment in half months after it debuted to

TOKYO--Japan's health ministry has approved Leqembi, a drug for Alzheimer’s disease that was jointly developed by Japanese and U.S. pharmaceutical companies.... The price is yet to be decided but is expected to be expensive, Kyodo News agency reported. Eisai is committed to delivering Leqembi to people who need it and their families “ as a new treatment, ” said Haruo Naito, the company’s CEO.... “ We aim to create impact on issues surrounding dementia in Japanese society," he said....

The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass.... The drug is the